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Respondent prefer to give to the young and to those who are worse off, either now
(quality of life), or in the future (prognosis). Elderly individuals, more often, prefer 
not to prioritize. It is estimated that an additional life year in a 20 year old is worth 
12.8 times the value of an additional year in an 80 year old. An additional life
year given to someone with a life expectancy of ﬁ ve years is worth 2.12 times that of 
one given to someone with a life expectancy of 10 years. An additional life year in 
someone with a utility that is 0.25 lower than someone else it is worth 2.45 times 
more. CONCLUSIONS: All results indicate that people do not think that a QALY is
a QALY and that the value of life years depends on the age of the respondent, the
prognoses of the patients and the patients’ current quality of life.
UT4
SOCIAL PREFERENCES FOR EQ-5D HEALTH STATES: IS IT TIME
TO CALL “TIMEOUT” ON TTO?
Bailey HH1, Kind P2
1University of the West Indies, St. Augustine, Trinidad and Tobago, 2University of York, York, UK
The valuation of health beneﬁ t is arguably the most fundamental issue underpinning
all clinical and economic evaluation. However, there is disagreement about the choice
of method by which such valuation is established. Advice issued by HTA agencies
generally favours utility elicitation methods but there is growing support for simpler 
methods that evoke ordinal judgments. Decision-makers face difﬁ cult choices when 
reviewing evidence based on different valuation methods. OBJECTIVES: To examine 
the extent to which ordinal preferences captured through VAS ratings are preserved
by TTO utility elicitation methods. METHODS: The UK MVH study (n  3,395) 
provides the empirical basis for the EQ-5D values required in economic evaluations 
submitted to NICE. This study collected both VAS ratings and TTO utilities for 13
EQ-5D health states per respondent. These data have been re-analysed for the pur-
poses of this paper. RESULTS: Spearman’s Rank Correlation Coefﬁ cient (rho) for TTO 
and VAS valuations was computed on a within-subject basis for all respondents, yield-
ing a mean of 0.771. 45% of respondents had a Spearman’s rho of less than 0.80 
(equivalent to a mean absolute difference of 1.7 in ranking over all 13 states). Over 
85% of respondent’s TTO values differed in rank by more than 3/13 places when 
compared with VAS ratings. Respondent characteristics did not account for differences 
in rankings of TTO and VAS scores. CONCLUSIONS: This study shows that for 
almost half the MVH respondents, TTO utilities did not coincide with ordinal prefer-
ences as revealed by their VAS scores. These results challenge a number of basic
assumptions – about the transformation of ordinal values into cardinal utilities; the 
superiority of TTO over VAS methods and the extent to which TTO “accurately”
represents individual preferences at all. Ultimately they undermine the status of TTO 
as a legitimate measure of preferences in social decision-making.
PODIUM SESSION II: HEALTH CARE DECISION-MAKER’S
CASE STUDIES II
CASE4
DIABETES PHYSICIAN RECOGNITION IN A LARGE HEALTH PLAN
Kramer M1, Perez HE2, Stacy T2
1Aetna, Brunswick, MD, USA, 2Total Therapeutic Management Inc, Kennesaw, GA, USA
ORGANIZATION: Aetna Inc. is one of the nation’s leading diversiﬁ ed health
care beneﬁ ts companies, serving approximately 37.2 million people. PROBLEM OR 
ISSUE ADDRESSED: To increase the number of physicians that are NCQA Diabetes 
Physician Recognition Program (DPRP) recognized in two pilot regions. GOALS:
(1) To increase the number of high-volume Aetna contracted practitioners (PCPs) 
located in targeted geographic areas (South Florida and Southeast PA) with Diabetes
Physician Recognition Program (DPRP) recognition (2) To provide physicians
with tools to support the delivery and recognition of consistent high quality care. 
OUTCOMES ITEMS USED IN THE DECISION: Clinical efﬁ cacy/effectiveness 
IMPLEMENTATION STRATEGY: The Aetna National Quality Management Diabe-
tes Work Group met and agreed on the implementation of a three phase program to
increase the number of NCQA DPRP recognized practitioners. Aetna conducted an 
analysis of two service areas (South FL and Southeastern PA) to rank the high volume 
Aetna contracted practitioners with the most Aetna members over the age of 18 with 
a diagnosis of diabetes. The member must have been under the care of the practitioner 
in calendar year 2007. For the practitioner to qualify he must have at least 25 Aetna 
members meeting this criteria. Forty practitioners were recruited into the program 
(20 from each service area). Aetna utilized Total Therapeutic Management (TTM),
a research organization, to implement the three phase program. In phase 1, TTM
recruited the qualifying practitioners and conducted an in- ofﬁ ce chart review to
abstract data consistent with the Comprehensive Diabetes Care Healthcare Effective-
ness Data and Information Set (HEDIS) measures. TTM utilized its Diabetes Perfor-
mance and Enhancement Program (DPReP) electronic application to provide the 
practitioners with a report to see if they met the point criteria for recognition. In phase
2, TTM conducted face-to-face outreach to discuss recognition standing, patient con-
sults (ClinAdvisor), and pharmacy compliance reports. The ClinAdvisor patient con-
sults detailed clinical outcomes such as, A1C, BP, LDL goal, etc. Also during the visit
Aetna-developed tools were provided such as chart stickers, eye exam report forms,
and 3-year diabetes checklist to promote quality improvement in tracking and manag-
ing members with diabetes. TTM communicated with the practitioner during the six-
month waiting period in areas that needed improvement. In phase 3, TTM conducted 
chart reviews based on the criteria set forth by NCQA. TTM input the abstracted 
data into its electronic application to evaluate recognition status. RESULTS: In order 
to achieve diabetes recognition, practitioners must have a cumulative score of 75
points or more from ten measures related to diabetes care. Of the 40 practitioners 
that participated in the program four had the potential points necessary to meet the
recognition standing score of 75 points in the initial evaluation. After the second 
review conducted approximately six months after the ﬁ rst review, 18 practitioners 
agreed to participate in phase 3. Of the 18 practitioners participating, 17 practitioners 
met the criteria for DPRP recognition. LESSONS LEARNED: Practitioners are aware 
of the beneﬁ ts of Pay for Performance initiatives. They are also aware of the various 
recognition programs available through NCQA. Practitioners have expressed concern 
about the time or ofﬁ ce staff necessary to conduct their own chart reviews and submit
the application to become a recognized provider. If there is a process in place to 
conduct chart reviews and provide chart review-based recommendations and other
practitioner tools, there is a strong possibility that more practitioners can meet the
requirements set forth by NCQA to become a DPRP recognized provider for diabetes 
and other conditions.
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HARMACOECONOMIC APPLICATIONS IN FORMULARY MANAGEMENT: 
A CASE STUDY OF ERLOTINIB AT A MAJOR CANCER CENTER
Lal LS1, Ugwu C2, DaCosta Byﬁ eld S1, Miller LA1, Arbuckle R1
1University of Texas M.D. Anderson Cancer Center, Houston, TX, USA, 2University of 
Houston, Houston, TX, USA
ORGANIZATION: University of Texas- MD Anderson Cancer Center (M. D. Ander-
son). PROBLEM OR ISSUE ADDRESSED: Budgets for cancer treatments are rising 
steadily with the advent of newer targeted therapies, in an era of health care cost 
containment. The issues of budgetary constraints and formulary management create
pressure on maintaining an economically viable formulary. We conducted a pre-
approval and post-approval analysis of erlotinib, an oral anti-neoplastic agent, in stage 
IIIB/IV non-small cell lung cancer (NSCLC) in the outpatient and inpatient setting at 
a tertiary cancer center as part of our Formulary Management System (FMS). GOALS:
The goal of this study is to evaluate and analyze the budget impact of erlotinib in
stage IIIB/IV NSCLC at a tertiary cancer center. The objective of the Drug Use Policy 
and Pharmacoeconomic Department is to utilize current clinical indications, resource
utilization, and cost information to perform a budget impact analysis, as part of the 
economic analysis of all new drugs considered for inclusion into the institutional 
Formulary. An economic assessment (pre-analysis) was conducted at the time of for-
mulary evaluation and addition in May 2005, and a reassessment and budget impact 
re-evaluation (post-analysis) was executed 12 months after formulary approval, from 
June 2006 to May 2007. OUTCOMES ITEMS USED IN THE DECISION: The fol-
lowing data were collected: the number of patients; the dose amount; the number of 
doses; the number of cycles; the purchase cost, the charge amount; and the reimburse-
ment amount. The budget impact analysis was executed using direct pharmaceutical 
costs adjusted to January 2008 US dollars with the aid of the Producer Price Index 
(PPI) from the U.S. Bureau of Labor Statistics. IMPLEMENTATION STRATEGY:
The pre-approval model was based on the FDA approval of erlotinib as a second line 
therapy in stage IIIB/IV NSCLC. Parameters, such as median duration of treatment 
and indications, were gathered from published clinical trials and the expected number 
of patients were estimated from expert opinion of clinicians. The pre-approval analysis 
model estimated that it would cost the institution $1,484,220 to treat 347 stage IIIB/IV
NSCLC patients for 67 days with erlotinib. This data along with a monograph was
presented to the Pharmacy and Therapeutics (P&T) committee and the drug was 
approved to be added to the institutional Formulary. RESULTS: A reassessment and
budget impact (post-approval) analysis was executed 12 months after erlotinib was 
inducted into the formulary. The analysis reviewed the non-investigational use of 
erlotinib from June 2006 to May 2007. We had 306 patients that received erlotinib 
during that time. The number of patients using erlotinib in the outpatient setting was 
267 (87%), and on the inpatient side 39 (13%) patients utilized the drug. 155 patients 
(51%) received erlotinib as second or third line therapy for treatment of stage IIIB/IV 
NSCLC, which is lower than what the pre-approval model predicted. Sixty patients 
(20%) were on erlotinib as ﬁ rst-line therapy for locally advanced, unresectable, or
metastatic pancreatic cancer, a second indication for the drug, attained after addition 
to the institutional formulary. Finally, ninety-one patients (30%) were on erlotinib for
other non-FDA approved caner indications. The overall annual budget for total erlo-
tinib usage was similar to the initial model, $1,473,085. The budget speciﬁ cally for 
NSCLC was lower at $858,904, only 58% of the predicted amount. One possible 
reason for the lower than predicted budget impact is that erlotinib is an oral agent,
which gives patients the option of obtaining the drug from an outside pharmacy closer 
to their home, rather than utilizing the institutional pharmacy. We also evaluated the 
reimbursement data for these patients, from June 2006 to May 2007, adjusting all 
values to January 2008 dollars. The reimbursement to charge ratio for NSCLC was
65%; 62% for pancreatic cancer; and 65% for the other non-FDA approved indica-
tions. Overall, the reimbursement to charge ratio for all 306 patients was 64%, which 
is favorable to our budget expectations at the institution. LESSONS LEARNED: The 
purpose of this assessment and budget impact analysis pre-and post-approval of 
the drug onto the formulary is to evaluate the budget impact of having erlotinib on
the formulary, assessing our actual utilization patterns. We were able to meet the 
reimbursement goals for the institution for all indications of erlotinib. Performing an
annual budget impact evaluation before addition of a drug to an institution’s formu-
lary, and comparing it with the annual budget impact after a sufﬁ cient time has elapsed
for penetration of product within the institution, is an essential process in determining 
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the best use of expensive resources. Continued improvements to this process are 
ongoing, by incorporating off-label estimates into the original model.
CASE6
PILOT PROJECT: INTEGRATING ADMINISTRATIVE AND FINANCIAL
DATABASES TO ESTIMATE PRICE OF HOSPITALIZATIONS
Wong H1, Levit K2
1Agency for Healthcare Research and Quality, Rockville, MD, USA, 2Thomson Reuters/
Agency for Healthcare Research and Quality, Washington, DC, USA
ORGANIZATION: Agency for Healthcare Research and Quality (funding organiza-
tion) Thomson Reuters. PROBLEM OR ISSUE ADDRESSED: Hospital administrative
data have been used in “cost-effectiveness”, “cost-beneﬁ t”, and “burden-of-illness” 
studies because they contain large numbers of cases for speciﬁ c conditions and proce-
dures and because charge information is available. While these data generally contain
information on how much the facility charged for the hospital stay, they lack informa-
tion on the cost to provide care and the amount reimbursed for care. In the past,
AHRQ developed a set of hospital-level cost-to-charge ratios to estimate the cost of 
providing care. Currently, AHRQ is piloting a project to create price-to-charge ratios 
that will be used in conjunction with charge information collected on hospital dis-
charge records to estimate the “price” of inpatient hospital care. In developing price-
to-charge ratios, the term “price” reﬂ ects the amount that hospitals are paid by
insurers and consumers based on payer revenue information for each hospital. This 
is the amount of revenue that hospitals actually receive, net of any discounts negotiated 
with insurers. These ratios will be linked to the Healthcare Cost and Utilization Project
(HCUP) State Inpatient Databases (SID). The HCUP SID ﬁ les contain the universe of 
inpatient discharge abstracts (including information on charges) in participating
States, translated into a uniform format to facilitate multi-State comparisons and 
analyses. Currently, 40 states participate in HCUP, encompassing about 90 percent of 
all U.S. community hospital discharges. The impetus for this pilot is the President’s 
and Secretary Leavitt’s initiatives to make health care information more transparent
to consumers. While the addition of price information will help consumers make more
informed choices about hospitalizations for themselves and their families, this infor-
mation will also be valuable for researchers by providing alternatives to measuring
resource use that are better suited for their studies. GOALS: The short-term goals of 
this project include: • Explore the feasibility of creating prices for common hospital
diagnoses. • Release prices at a state-wide level for four broad payer groups (Medicare,
Medicaid, Private, and self-pay) and groupings of conditions. • Increase understanding 
of pricing differences among payers. • Release the data publicly after some internal
validation. The long term goals of this project include: • Develop price-to-charge ratios 
for all hospitals by payer states using modeling techniques. • Link price-to-charge 
ratios to the HCUP databases, which currently contain charge information and
estimate costs. • Validate estimated prices with data sources such as CMS, Market 
Scan, • Provide states with information on hospital average prices that can be used 
to populate a Website where consumers can explore pricing for common diagnoses. 
• Release prices publicly on additional AHRQ databases, including national databases
such as the Nationwide Inpatient Sample (NIS) and Kids’ Inpatient Database (KID).
OUTCOMES ITEMS USED IN THE DECISION: HCUP data have been used in 
“cost-effectiveness”, “cost-beneﬁ t”, and “burden-of-illness” studies because they 
contain large numbers of cases for speciﬁ c conditions and procedures and because
charge and estimated cost information is available. The addition of estimates prices
will provide researchers an additional tool to more effectively conduct their studies. 
IMPLEMENTATION STRATEGY: AHRQ solicited participation of HCUP Partner 
organizations that have access to hospital revenue information by payer, and are
willing to release state-level charge and price information broken out by the four broad 
payer groups and broad diagnostic categories. Initially, AHRQ is utilizing information
from 5 HCUP SID Partner States in conjunction with hospital-speciﬁ c revenue infor-
mation to develop prices for hospitalizations. RESULTS: This project is on-going and
making substantial progress. Five states with the required ﬁ nancial information have
been identiﬁ ed. The analytic methods to validate the data have been determined. The 
plan to create the price-to-charge ratios for these states is in place. An illustrative 
example of a speciﬁ c condition or procedure will be provided during the presentation
to demonstrate the differences in resource use as measured by “charges,” “costs,” and 
“prices.” An explanation of what these concepts are capturing will also be presented.
LESSONS LEARNED: To date, the project the lessons learned include: 1. The number
of States that collect ﬁ nancial information by major payers for each hospital are
limited. 5 States have been identiﬁ ed that have the detailed information required. As 
the study moves forward, our objective is to identify 8–10 states with this level of 
information. 2. While States may collect gross and net revenue information by payer,
not all separate these revenues completely for inpatient and outpatient services.
Methods will be developed to address this issue. 3. Deﬁ nitions of revenues and the
level of detailed data collection vary considerably among States. These differences will
be reconciled.
PODIUM SESSION II: RESEARCH ON METHODS – Cost & Clinical
Outcomes Methods
CO1
EVIDENCE-BASED TIME HORIZON FOR THE INTERVENTIONS
IN PHARMACOECONOMIC MODELS
Farahani P
Berkshire Medical Center, University of Massachusetts Medical School, Pittsﬁ eld, MA, USA
When the measurement of a long-term outcome is necessary, selecting evidence-based 
time horizons according to pharmacoepidemiology data is crucial. OBJECTIVE: To 
illustrate the effect of assumed time horizon for the interventions in pharmacoeco-
nomic models on measured outcomes. METHODS: The beneﬁ t of reducing LDL-C 
was incorporated into a model to calculate reduction in cardiovascular events and
resulted economic outcomes. Data for LDL-C reduction from a head-to-head RCT 
[Am Heart J 2002;144:1044–51]; rosuvastatin (starting 5 mg) versus atorvastatin 
(starting 10 mg) with up-titration doses were incorporated into the model; and distri-
bution of cardiovascular risk for users [N  100,000, duration ﬁ ve years] in Canadian 
population [Clin Invest Med 2007;30:E63-E69] were assumed. To ﬁ nd out the effect
of time horizon on economic evaluation of therapeutics, the component of ﬁ ve years 
was changed to ten years time horizon. RESULTS: Using ﬁ ve years duration of therapy,
rosuvastatin and atorvastatin can prevent 9505 and 8702 cardiovascular events (non-
fatal MI and stroke), respectively. Reduction in non-fatal MI and stroke can be 
translated to $252,300,392 (CDN) and $230,980,624 direct cost savings, respectively
($288,871,921 and $158,510,416 total net-beneﬁ t). With ten years assumption 
for statin therapy, rosuvastatin and atorvastatin can prevent 25948 and 22190 car-
diovascular events, respectively. The prevention of cardiovascular events according
to the model based on ten years time horizon were calculated 2.73 and 2.55 times
higher than the ﬁ ve years based model for rosuvastatin and atorvastatin, respectively. 
CONCLUSION: This simulation study illustrates the effect of incorporated time 
horizons in pharmacoeconomic models on the resulted outcomes. Therefore, consider-
ing an evidence-based time horizon for the model is essential. For example, in this 
study Canadian community-based clinical practice data reported a median of approxi-
mately ﬁ ve years of statin therapy for the patients. Therefore, a time horizon of ﬁ ve 
years was assumed to be an evidence-based time horizon for the model.
CO2
METHODS FOR INTERPRETING AND DISPLAYING RESULTS: 
FROM REGRESSION MODELS: BEYOND BETAS AND ODDS RATIOS
Ganz M
Abt Bio-Pharma Solutions, Inc. and Harvard School of Public Health, Lexington, MA, USA
OBJECTIVE: To present practical methods for interpreting and displaying results from 
regression models that mitigate the risk of miscommunication and misinterpretation.
METHODS: A series of examples of correct and incorrect ways of presenting results 
from regression models will be presented from the recently published pharmacoeco-
nomics and outcomes research literature. Methods for computing expected values and
predicted probabilities from ordinary least squares (OLS) and logistic regression 
models will be presented. RESULTS: Computing and presenting expected values and 
predicted probabilities can, and have in some of the published literature, resulted in
less ambiguous and easier to interpret results. CONCLUSION: As pharmacoecono-
mists, we are called on to the present our results not only to our colleagues, but also
to policy-makers and the lay media. Therefore, it is important to make sure results 
from complicated regression analyses are properly communicated and interpreted. 
However, coefﬁ cients from all but the simplest models are often incorrectly interpreted. 
Odds ratios from logistic regression models are even more likely to be misinterpreted 
(as risk ratios). Furthermore, simply reporting odds ratios does not convey information
about the probability of outcomes occurring for reference group(s). It will be argued 
that computing and presenting the expected value, E(Y), from an OLS model and the 
predicted probability, Pr(Y), from a logistic regression can help researchers better “tell
a story” and result in less ambiguous presentations of ﬁ ndings. For example, the 
adjusted expected costs of an intervention can be computed for different doses and
for different demographic groups and the predicted probability of medication adher-
ence can also be computed as a function of different combinations of patient demo-
graphic characteristics and attitudes.
CO3
ESTIMATING DRUG COSTS IN ECONOMIC EVALUATIONS IN
IRELAND AND THE UK: AN ANALYSIS OF PRACTICE AND
RESEARCH RECOMMENDATIONS
Hughes DA1, Tilson L2, Drummond MF3
1Bangor University, Bangor, UK, 2National Centre for Pharmacoeconomics, Dublin, Ireland, 
3University of York, York, Heslington, UK
OBJECTIVES: The cost of the drug of interest, its comparator(s) and concomitant 
drugs, are important parameters in pharmacoeconomic evaluations. Although general
methods guidelines exist, there are no speciﬁ c recommendations on drug cost estima-
tion. The aim of this study was to assess current practice in the reporting and conduct
of drug costing in Ireland and the UK, and make recommendations for improving 
future practice. METHODS: We searched the NHS Economic Evaluation Database 
for evaluations published in Ireland between 2001–2006. Due to the large number of 
UK studies, we considered only those published between 2005–2006. To assess the 
generalisability of our ﬁ ndings we included studies from Denmark, Finland and
Norway published between 2001–2006. This generated 59 studies. Data were
extracted on: name(s) of medicine(s), route of administration, source of drug cost, cost 
